Health Professional Radio - Podcast

Returning guest, Dr. David Spetzler, President and Chief Scientific Officer at Caris® Life Sciences discusses partnering with Merus, a clinical-stage oncology company, to detect neuregulin 1 (NRG1) fusions in cancer patients using Caris’ whole exome and whole transcriptome sequencing. The goal of this collaboration is to use Caris’ extensive suite of breakthrough next-generation sequencing technology to identify patients who may be eligible for Merus’ bispecific antibody Zenocutuzumab (“Zeno”) Phase 1/2 eNRGy trial and Early Access Program.